MDM2(12q15) Gene Amplification- FISH

What is the function of the mdm2 gene?

The mdm2 gene is an important gene involved in a wide range of cellular processes. It is a negative regulator of the tumor suppressor p53, which helps regulate cell growth and prevent tumor development. It also binds to several other proteins involved in cell cycle regulation, DNA repair, and apoptosis, making it an essential gene for proper cellular functioning. In addition, mdm2 has been found to be involved in the development of certain types of cancer and has been implicated in chemotherapy resistance. Therefore, it is clear that the mdm2 gene plays a vital role in many different cellular processes.

What is the significance of mdm2 (12q1, gene amplification?

Mdm2 (12q1, gene amplification) is a gene that plays an important role in the regulation of the p53 tumor suppressor gene. The increased expression of Mdm2 in cells with amplified p53 gene is a major mechanism for its anti-apoptotic effects. This is significant because it is a key factor in understanding the relationship between p53 and cancer. Research has shown that increased expression of Mdm2 in cells with amplified p53 gene is associated with more aggressive tumors and worse prognoses in cancer patients. Thus, understanding the role of Mdm2 in regulating p53 is important for the development of new treatments and therapies to combat cancer.

How common is mdm2 (12q1, gene amplification?

Mdm2 (12q1) gene amplification test in is not a common phenomenon. It is found in certain types of cancer, primarily in soft tissue sarcomas, breast cancer, and chronic myeloid leukemia. It is also seen at low frequency in other cancers, such as prostate cancer and ovarian cancer. Mdm2 gene amplification is believed to be associated with an increased risk of cancer development and progression, as well as drug resistance. However, it is still not clear how or why the gene is amplified in some tumors.

What are some of the risk factors associated with mdm2 (12q1, gene amplification?

Mdm2 (12q1, gene amplification) is a genetic abnormality that is linked to a number of different cancers, including certain types of leukemia and some types of lymphomas. It is caused by an increase in the number of copies of the Mdm2 gene that is present in the cells of the body. This increase in gene copies can lead to increased activity of the gene, which in turn can encourage the growth and spread of cancer cells.

Some of the risk factors associated with mdm2 (12q1, gene amplification) include a family history of cancer, exposure to radiation, and certain lifestyle choices. Additionally, individuals with certain genetic predispositions may be at an increased risk for developing mdm2 (12q1, gene amplification).

It is important to note that not everyone who has Mdm2 (12q1) gene amplification test cost is Rs. 7,000 will develop cancer, but those who do have a higher risk of developing certain types of cancer. It is important to talk to your doctor about any concerns you may have regarding your risk level.

DESCRIPTION – This test detects for the amplification of MDM2 gene for classification of certain adipocytic tumors. MDM2 amplification are frequently detected in well differentiated liposarcoma which includes atypical lipomatous tumor and in dedifferentiated in liposarcoma. These tumors can be difficult to distinguish morphologically from other high grade sarcomas and benign tumors. Amplifications are detected infrequently in other soft tissues sarcomas, and are not detected in benign lipomas.

Methodology – fluorescence in situ hybridization (FISH)
Turn Around Time – 6 days
Patient Preparation –
Collect – tumor tissue
Specimen Preparation – formalin fixed paraffin embedded tissue block. Protect the slides from excessive heat.
Storage/Transport Temperature – room temperature (18-25 degrees C)
STABILITY – ambient: indefinitely; refrigerated: indefinitely
Unacceptable Conditions – alternate fixatives and decalcified specimens
MRP – 7000.00
Special Instructions – tissue block must contain 10% of tumor tissue. Clinical history is mandatory including surgical pathology reports